These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33843698)

  • 21. Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
    Frasier MA
    Per Med; 2017 Jan; 14(1):13-15. PubMed ID: 29749821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
    Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease.
    Mathur S; DeWitte S; Robledo I; Isaacs T; Stamford J
    J Parkinsons Dis; 2015; 5(2):263-8. PubMed ID: 25720445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the Diverse and Inclusive Future of Parkinson's Disease Genetics and Its Widespread Impact.
    Elsayed I; Martinez-Carrasco A; Cornejo-Olivas M; Bandres-Ciga S
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
    Cohen S; Waks Z; Elm JJ; Gordon MF; Grachev ID; Navon-Perry L; Fine S; Grossman I; Papapetropoulos S; Savola JM
    BMC Med Inform Decis Mak; 2018 Dec; 18(1):138. PubMed ID: 30572891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palliative care for Parkinson's disease: a summary of the evidence and future directions.
    Richfield EW; Jones EJ; Alty JE
    Palliat Med; 2013 Oct; 27(9):805-10. PubMed ID: 23838377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding how people with Parkinson's disease and their relatives approach advance care planning.
    Churm D; Dickinson C; Robinson L; Paes P; Cronin T; Walker R
    Eur Geriatr Med; 2022 Feb; 13(1):109-117. PubMed ID: 34398428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update to 2019-2022 ONS Research Agenda: Rapid Review to Promote Equity in Oncology Healthcare Access and Workforce Development.
    Jones RA; Hirschey R; Campbell G; Cooley ME; Somayaji D; Lally R; Rueter EK; Gullatte MM
    Oncol Nurs Forum; 2021 Nov; 48(6):604-612. PubMed ID: 34673761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Kane PB; Benjamin DM; Barker RA; Lang AE; Sherer T; Kimmelman J
    Mov Disord; 2021 Jan; 36(1):171-177. PubMed ID: 33002259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing Social Mission Research: A Call to Action.
    Erikson C; Ziemann M
    Acad Med; 2022 Jan; 97(1):30-36. PubMed ID: 34554947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Rizig M; Bandres-Ciga S; Makarious MB; Ojo OO; Crea PW; Abiodun OV; Levine KS; Abubakar SA; Achoru CO; Vitale D; Adeniji OA; Agabi OP; Koretsky MJ; Agulanna U; Hall DA; Akinyemi RO; Xie T; Ali MW; Shamim EA; Ani-Osheku I; Padmanaban M; Arigbodi OM; Standaert DG; Bello AH; Dean MN; Erameh CO; Elsayed I; Farombi TH; Okunoye O; Fawale MB; Billingsley KJ; Imarhiagbe FA; Jerez PA; Iwuozo EU; Baker B; Komolafe MA; Malik L; Nwani PO; Daida K; Nwazor EO; Miano-Burkhardt A; Nyandaiti YW; Fang ZH; Obiabo YO; Kluss JH; Odeniyi OA; Hernandez DG; Odiase FE; Tayebi N; Ojini FI; Sidranksy E; Onwuegbuzie GA; D'Souza AM; Osaigbovo GO; Berhe B; Osemwegie N; Reed X; Oshinaike OO; Leonard HL; Otubogun FM; Alvarado CX; Oyakhire SI; Ozomma SI; Samuel SC; Taiwo FT; Wahab KW; Zubair YA; Iwaki H; Kim JJ; Morris HR; Hardy J; Nalls MA; Heilbron K; Norcliffe-Kaufmann L; ; ; ; ; Blauwendraat C; Houlden H; Singleton A; Okubadejo NU;
    Lancet Neurol; 2023 Nov; 22(11):1015-1025. PubMed ID: 37633302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cells. $2.2 million for cells to fight Parkinson's.
    Holden C
    Science; 2001 Sep; 293(5537):1966. PubMed ID: 11557848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Home and health in people ageing with Parkinson's disease: study protocol for a prospective longitudinal cohort survey study.
    Nilsson MH; Iwarsson S
    BMC Neurol; 2013 Oct; 13():142. PubMed ID: 24107116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease.
    Deane KH; Flaherty H; Daley DJ; Pascoe R; Penhale B; Clarke CE; Sackley C; Storey S
    BMJ Open; 2014 Dec; 4(12):e006434. PubMed ID: 25500772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex and Gender Differences in Parkinson's Disease.
    Patel R; Kompoliti K
    Neurol Clin; 2023 May; 41(2):371-379. PubMed ID: 37030964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diversity, equity, and inclusion within the Society for Pediatric Anesthesia: A mixed methods assessment.
    Reece-Nguyen TL; Lee HH; Garcia-Marcinkiewicz AG; Szolnoki J; Fernandez AM; Mukkamala S; Lalwani K; Deutsch N; Jimenez N
    Paediatr Anaesth; 2023 Jun; 33(6):435-445. PubMed ID: 36715575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science.
    Byams VR; Baker JR; Bailey C; Connell NT; Creary MS; Curtis RG; Dinno A; Guelcher CJ; Kim M; Kulkarni R; Lattimore S; Norris KL; Ramirez L; Skinner MW; Symington S; Tobase P; Vázquez E; Warren BB; Wheat E; Buckner TW
    Expert Rev Hematol; 2023 Mar; 16(sup1):87-106. PubMed ID: 36920863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.